AstraZeneca's ZD0473 in resistant tumors

17 May 2001

New results from a Phase II monotherapy trial of AstraZeneca'snew-generation platinum drug ZD0473 have shown that the agent has a favorable side-effect profile and can produce objective clinical responses in patients with both platinum-sensitive and -resistant ovarian cancer. ZD0473 has a number of potential tolerability advantages over cisplatin, the most commonly-used drug in the platinum class, according to study investigator Martin Gore of the Royal Marsden Hospital in London, UK, including a reduced risk of toxicity to the kidney and nervous system. Another study has shown that ZD0473 is also active in cisplatin-resistant non-small cell lung cancer patients.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight